This database contains 472 studies, archived under the term: "Pharmaceutical Interventions"
Click here to filter this large number of results.
Effect of cholinergic stimulation in early Alzheimer’s disease – functional imaging during a recognition memory task
Miettinen, Pekka S.,
Pihlajamäki, Maija,
Jauhiainen, Anne M.,
Tarkka, Ina M.,
Gröhn, Heidi,
Niskanen, Eini,
Hänninen, Tuomo,
Vanninen, Ritva,
Soininen, Hilkka
Treatment of Alzheimer’s disease (AD) with acetylcholinesterase inhibitors (AChEI) enhances cholinergic activity and alleviates clinical symptoms. In the present functional magnetic resonance imaging (fMRI) study, we investigated the effect of the AChEI rivastigmine on cognitive function and brain activation patterns during a face recognition memory task. Twenty patients with newly-diagnosed mild AD were administered a […]
In vivo assessment of amyloid-β deposition in nondemented very elderly subjects
Mathis, Chester A.,
Kuller, Lewis H.,
Klunk, William E.,
Snitz, Beth E.,
Price, Julie C.,
Weissfeld, Lisa A.,
Rosario, Bedda L.,
Lopresti, Brian J.,
Saxton, Judith A.,
Aizenstein, Howard J.,
McDade, Eric M.,
Kamboh, M. Ilyas,
DeKosky, Steven T.,
Lopez, Oscar L.
Objective: This study examined amyloid-β (Aβ) deposition in 190 nondemented subjects aged ≥82 years to determine the proportion of Aβ-positive scans and associations with cognition, apolipoprotein E (APOE) status, brain volume, and Ginkgo biloba (Gb) treatment.; Methods: Subjects who agreed to participate had a brain magnetic resonance imaging and positron emission tomography scan with (11) […]
Dopamine D₂-agonist rotigotine effects on cortical excitability and central cholinergic transmission in Alzheimer’s disease patients
Martorana, Alessandro,
Di Lorenzo, Francesco,
Esposito, Zaira,
Lo Giudice, Temistocle,
Bernardi, Giorgio,
Caltagirone, Carlo,
Koch, Giacomo
Dopamine is a neurotransmitter involved in several brain functions ranging from emotions control, movement organization to memory formation. It is also involved in the regulation of mechanisms of synaptic plasticity. However, its role in Alzheimer’s disease (AD) pathogenesis is still puzzling. Several recent line of research instead indicates a clear role for dopamine in both […]
Utilisation of atypical antipsychotic drugs in institutionalised elderly persons and prevalence of metabolic alterations
Martínez Romero, G.,
Peris Martí, J.F.,
Gomar Fayos, J.,
Navarro Gosalbez, M.,
Quintana Vargas, I.,
Muelas Tirado, J.
Objectives: Describe and evaluate atypical antipsychotics utilisation on the institutionalized elderly population of the Valencian Community and prevalence of associated metabolic alterations.; Material and Methods: Multicentre transversal descriptive study on medication utilisation and prevalence case-control of alterations of glycaemia, cholesterol and triglycerides. The statistical analysis of metabolic alterations is performed from the difference in prevalence […]
Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington’s disease
Lundin, Anders,
Dietrichs, Espen,
Haghighi, Sara,
Göller, Marie-Louise,
Heiberg, Arvid,
Loutfi, Ghada,
Widner, Håkan,
Wiktorin, Klas,
Wiklund, Leif,
Svenningsson, Anders,
Sonesson, Clas,
Waters, Nicholas,
Waters, Susanna,
Tedroff, Joakim
Objectives: To evaluate the efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington’s disease (HD).; Methods: In a randomized, double-blind, placebo-controlled, 4-week trial, patients with HD received pridopidine (50 mg/d, n = 28) or placebo (n = 30). The primary outcome measure was the change from baseline in weighted cognitive score, […]
A phase II trial of tideglusib in Alzheimer’s disease
Lovestone, Simon,
Boadab, Mercè,
Dubois, Bruno,
Hüll, Michael,
Rinne, Juha O.,
Huppertz, Hans-Jürgen,
Calero, Miguel,
Andrés, María V.,
Gómez-Carrillo, Belén,
Leon, Teresa,
del Seri, Teodoro
Background: The ARGO study was a phase II, double-blind, placebo controlled, four parallel arm trial of tideglusib in Alzheimer’s disease (AD). Objective: To prove the clinical efficacy of an inhibitor of glycogen synthase kinase-3 (GSK-3), in AD. Methods: Mild to moderate (Mini-Mental State Examination (MMSE) score, 14–26) AD patients on cholinesterase inhibitor and/or memantine treatment […]
The effect of an aloe polymannose multinutrient complex on cognitive and immune functioning in Alzheimer’s disease
Lewis, John E.,
McDaniel, H. Reginald,
Agronin, Marc E.,
Loewenstein, David A.,
Riveros, Jorge,
Mestre, Rafael,
Martinez, Mairelys,
Colina, Niurka,
Abreu, Dahlia,
Konefal, Janet,
Woolger, Judi M.,
Ali, Karriem H.
Alzheimer’s disease (AD) is a leading killer of Americans, imparts a significant toll on the quality of life of the patient and primary caregiver, and results in inordinate costs in an already overburdened medical system. Prior studies on cholinesterase inhibitors among AD patients have shown minimal amelioration of disease symptoms and/or restoration of lost cognitive […]
Memantine improves goal attainment and reduces caregiver burden in Parkinson’s disease with dementia
Objective: Memantine, an uncompetitive antagonist of N‐methyl‐D‐aspartate receptors, may have a role in managing symptoms associated with dementia in Parkinson’s disease (PDD), although its role in improving patient‐reported outcomes (PROs) has not been extensively investigated. PROs may be more sensitive than standard psychometric measures for detecting change in complex conditions such as PDD. The aim […]